We measured the protein levels of NOX2 in glial fibrillary acidic protein (GFAP)-positive glioma cells in patients with high-grade glioma (grade 4 (G4), GBM (n = 3), and grade 3 (G3), anaplastic astrocytoma (n = 3)) and low-grade glioma (grade 1 (G1), ganglioglioma (n = 2), and grade 2 (G2), diffuse astrocytoma (n = 3)) using immunofluorescence staining (Figures 1a and S1). This evidence concerns the gene GFAP and central nervous system cancer.